The biopharmaceutical contract manufacturing market is projected to reach US$ 27,868.50 million by 2028 from US$ 15,735.04 million in 2021; it is expected to grow at a CAGR of 8.5% from 2021 to 2028. The rising outsourcing by pharmaceutical companies is one of the most key factors driving the growth of the market. A few years ago, the contract manufacturing industry was a niche service market offering additional manufacturing capacity or specific services to pharmaceutical companies. The rise of CMOs was fueled by the increasing number of drug manufacturing failures. In the past, pharmaceutical companies had undertaken manufacturing facilities to develop innovative drugs. However, to reduce the risk of overcapacities, the demand for manufacturing outsourcing has continuously risen.

Top Companies Analysis-

Lonza AG
Boehringer Ingelheim Biopharmaceuticals GmbH
Inno Bio Ventures Sdn Bhd
Thermo Fisher Scientific, Inc
AbbVie, Inc
WuXi Biologics, Inc
General Electric Co
Samsung Biologics Co. Ltd
Merck KGaA
Ajinomoto Co. Inc

Recently, Revolo Biotherapeutics entered into a partnership with contract development and manufacturing organization (CDMO)—Northway Biotech—to manufacture Revolo’s binding immuno-regulatory protein 1805. The partnership included services from cell line development to manufacturing protein with quality assurance and regulatory compliance support. Similarly, Gland Pharma has been manufacturing Remdesivir for four companies, including Mylan, since 2021. Also, the organization increased its manufacturing quotas due to high demand from the companies. In 2019, Samsung Biologics and GI Innovation signed a contract for immunochemotherapy. Under this agreement, Samsung Biologics was providing services ranging from f-cell lines development to production of Phase-I drug substances. The increasing number of contracts between biopharmaceutical companies and contract manufacturing companies shows an increasing market size for the biopharmaceutical contract manufacturing market.
Leading Industry players and manufacturers are studied to help give a brief idea about them in the report. The challenges faced by them and the reasons they are on that position are explained to help make a well informed decision. Competitive landscape of Biopharmaceutical Contract Manufacturing Industry is given presenting detailed insights into the company profiles, developments, merges, acquisitions, economic status and best SWOT analysis.

The report is inclusive of product type outlook, application spectrum, end-use outlook, technology landscape, regional market analysis, and competitive overview.

Market Segments-

Biopharmaceutical Contract Manufacturing Market – Segmentation
Based on the product, the biopharmaceutical contract manufacturing market is segmented into biologics and biosimilar. The biologics segment is further segmented into monoclonal antibodies, recombinant proteins, vaccines, and others.

By service, the biopharmaceutical contract manufacturing market is segmented into process development, fill and finish operations, analytical and quality control studies, and packaging.

Based on the source, the biopharmaceutical contract manufacturing market is segmented into mammalian and microbial-based biologics/non-mammalian.

About Us:                    

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, and Chemicals

Contact Us:                        

If you have any queries about this report or if you would like further information, please

Contact Person: Sameer Joshi

E-mail: sales@theinsightpartners.com

Phone: +1-646-491-9876